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Voltage gated calcium channels (VGCCs) are well known for its importance in synaptic transmission in the peripheral
and central nervous system. However, the role of different VGCCs in the anterior cingulate cortex (ACC) has not been
studied. Here, we use a multi-electrode array recording system (MED64) to study the contribution of different types of
calcium channels in glutamatergic excitatory synaptic transmission in the ACC. We found that only the N-type calcium
channel blocker ω-conotoxin-GVIA (ω-Ctx-GVIA) produced a great inhibition of basal synaptic transmission, especially in
the superficial layer. Other calcium channel blockers that act on L-, P/Q-, R-, and T-type had no effect. We also tested
the effects of several neuromodulators with or without ω-Ctx-GVIA. We found that N-type VGCC contributed partially
to (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid- and (R)-Baclofen-induced synaptic inhibition. By contrast, the
inhibitory effects of 2-Chloroadenosine and carbamoylcholine chloride did not differ with or without ω-Ctx-GVIA,
indicating that they may act through other mechanisms. Our results provide strong evidence that N-type VGCCs
mediate fast synaptic transmission in the ACC.Background
It is well-known that voltage-gated Ca2+ channels (VGCCs)
play pivotal roles in neurotransmitter release and synaptic
transmission. Previous studies have discovered the role of
various types of calcium channels in peripheral regions [1],
spinal cord [2], cerebellum [3] and hippocampus [4-6].
These studies indicate that N- (CaV2.2) and P/Q-type
(CaV2.1) VGCCs play the most dominant role in basal syn-
aptic transmission in most of the neurons [7,8]. N-type is
more important in the peripheral nervous system and the
joint action of N- and P/Q-type is prominent in the cen-
tral nervous system [9,10]. These studies were per-
formed by using the ω-conotoxin GVIA (ω-Ctx GVIA) and
ω-agatoxin IVA (ω-Aga IVA), which specifically block the
N- and P/Q-type VGCCs, respectively.
Due to its important role in neuronal Ca2+ concentra-
tion regulation, VGCCs are crucial players in a range of* Correspondence: min.zhuo@utoronto.ca
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stated.physiological and pathological conditions including acute
nociception and chronic pain [11-13]. Among different
VGCCs, N- and T- type VGCCs are known to play
major roles in pain information processing [14,15] and
inhibiting VGCCs is thought to be useful for reducing
pain [16-18]. Ziconotide (SNX111; Prialt), a drug that tar-
gets N-type VGCC approved by the US Food and Drug
Administration and European Medicine Agency, is also
used intrathecally for severe chronic pain patients [18-21].
However, fewer studies have been reported for the role
of VGCCs in synaptic transmission in pain-related cor-
tical structures.
Convergent evidences from human and animal studies
show that neurons in the anterior cingulate cortex (ACC)
play important roles in pain perception and chronic pain
[22,23]. Our previous studies show that neuropathic pain
models induced long-term changes in excitatory synaptic
transmission in the ACC neurons of adult mice [24,25].
Inactivation of the frontal cortex, including the ACC,
by local lesions leads to the reduction of the nocicep-
tive responses and aversive behaviors associated with
chronic pain [26-29]. In situ hybridization brain atlas
from the Allen Institute for Brain Science shows thatd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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in the mouse ACC. Thus, in the present study, we used
a 64-channel multi-electrode dish (MED64) system, a
two-dimensional electrical activity monitoring device
[30-32], to characterize the role of different VGCCs in
adult mouse ACC glutamatergic synaptic transmission.
The MED64 system allowed us to detect the field exci-
tatory postsynaptic potentials (fEPSPs) at multiple sites
in the mouse ACC at the same time, which is difficult
to achieve with conventional field recording systems
[24,30]. We found that N-type VGCCs play the dominant
role in the ACC synaptic transmission and other VGCCs
such as P/Q-, L-, T-, and R-type do not play any important
role. Moreover, excitatory synaptic transmission in the




Adult (8–12 week old) male C57BL/6 mice were used.
All animals were housed under a 12 h light/dark cycle
with food and water provided ad libitum. All works were
conducted according to the policy and regulation for the
care and use of laboratory animals approved by Institu-
tional Animal Care and Use Committee in Seoul National
University and University of Toronto. The number of ani-
mals used and their suffering were greatly minimized.
Brain slice preparation
The general procedures for making ACC slices are simi-
lar to those described previously [30]. Briefly, adult male
mice were anesthetized with isoflorane and the brains
were removed and transferred to ice-cold artificial cere-
brospinal fluid (ACSF) containing (in mM): 124 NaCl,
2.5 KCl, 2 CaCl2, 2 MgSO4, 25 NaHCO3, 1 NaH2PO4, 10
glucose. This ACSF was used throughout the experiment.
Three coronal brain slices (300 μm), after the corpus cal-
losum meets, were cut using a vibratome (Leica, Hesse,
Germany). The slices were placed in a submerged recov-
ery chamber with oxygenated (95% O2, 5% CO2) ACSF at
room temperature for at least 2 h.
Preparation of the multi-electrode array
The procedures for preparation of the MED64 system
(Panasonic, Osaka, Japan) were similar to those as previ-
ously described [30-33]. The MED64 probe (MED-P515A,
8 x 8 array, interpolar distance 150 μm, Panasonic)
was superfused with ACSF (pH = 7.4) at 28–30°C, and
maintained at a 1 ~ 2 ml/min flow rate. One planar mi-
croelectrode with bipolar constant current pulses (1–
20 μA, 0.2 ms) was used for stimulation of the ACC
slice. The stimulation site was selected within the layer
V region. Before use, the surface of the MED64 probe
was treated with 0.1% polyethyleneimine (Sigma, St.Louis, MO, USA) in 25 mM borate buffer (pH 8.4) over-
night, at room temperature.
Field potential recording in adult ACC slices
After 2 h recovery, one ACC slice was placed in a MED
probe, and most of the 64 electrodes located within the
ACC. The slice was allowed to recover for 30 min before
the electrophysiological recording was attempted. Elec-
trical stimulation was delivered to one channel located
within the layer V of the ACC, and evoked fEPSPs were
monitored and recorded from the other 63 channels as
described previously [24,30]. The intensity of the stimuli
was approximately 40 ~ 60% of the intensity that induced
the maximal fEPSPs. Baseline responses were evoked at
0.017 Hz for 30 min. The data were averaged every 2 min.
Whole-cell patch-clamp electrophysiology
For whole-cell patch-clamp electrophysiology, slices were
individually transferred to a recording chamber on the
stage of a BX51WI microscope (Olympus, Tokyo, Japan)
equipped with infrared differential interference contrast
optics and superfused with the same ACSF at 2 ml/min
for visualized whole-cell patch-clamp recordings [34-37].
Excitatory postsynaptic currents (EPSCs) were recorded
from superficial layer (layer II-III) pyramidal neurons with
an Axon 200B amplifier (Axon Instruments, Union City,
CA, USA) and the stimulations were delivered by a bipolar
tungsten-stimulating electrode placed in the deep layer
(layer V-VI). AMPA receptor-mediated EPSCs were in-
duced by repetitive stimulations at 0.03 Hz, and neurons
were voltage clamped at −70 mV. The recording pipettes
(borosilicate glass, 3–5 MΩ) were filled with a solution
containing (in mM) 145 K-gluconate, 5 NaCl, 1 MgCl2,0.2
EGTA, 2 Mg-ATP, 0.1 Na3-GTP, 10 HEPES (adjusted to
pH 7.2 with KOH; 280–300 mOsm). The initial access re-
sistance (typically 15–30 MΩ) was monitored throughout
the experiment. Data were discarded if the access resist-
ance changed >15% during an experiment. Data were fil-
tered at 1 kHz, and digitized at 10 kHz.
Drugs
Drugs were freshly prepared: N-type VGCC blocker ω-Ctx
GVIA, P/Q-type VGCC blocker ω-Aga IVA and R-type
VGCC blocker SNX-482 were purchased from Peptide
Institute Inc. (Osaka, Japan). T-type VGCC blocker NiCl2
was obtained from Sigma. L-type VGCC blocker nimodi-
pine, metabotropic glutamate receptor (mGluR) agonist
(1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-
ACPD), cholinergic receptor agonist carbamoylcholine
chloride (carbachol, Cch), γ-Aminobutyric acid B (GABAB)
receptor agonist (R)-Baclofen and adenosine receptor
agonist 2-Chloroadenosine (2-CA) were purchased from
Tocris Bioscience (Bristol, UK). Drugs were stored in
frozen aliquots at −20°C. All drugs were diluted from the
Kang et al. Molecular Pain 2013, 9:58 Page 3 of 13
http://www.molecularpain.com/content/9/1/58stock solutions to the final desired concentration in the
ACSF before immediate use.
Data analysis
MED64 Mobius was used for data acquisition and ana-
lysis. The percentages of the fEPSP slopes were normal-
ized by the averaged value of the baseline period
(30 min). The reduction index is calculated as follows:
100% - the percentage change of fEPSP slope within the
last 4 min of the experiment. The value used for ‘end of
drug treatment’ was the averaged value of interval between
4 min before and 2 min after endpoint. Whole-cell patch-
clamp data were collected and analyzed using Clampex
10.2 and Clampfit10.2 software (Axon Instruments). All
data are presented as mean ± SEM. Statistical comparisons
were made using the t-test and one-way ANOVA by
SigmaPlot 11.0. Post hoc Bonferroni test was used for fur-
ther comparison. If the data did not pass the equal vari-
ance test, one way ANOVA was done in ranks and Dunn’s
method was used for post-hoc test. Two-way ANOVA and
Post hoc Bonferroni test was performed in the neuromo-
dulator experiment to compare layer difference. In all
cases, statistical significance was accepted at the P < 0.05
significance level.
Results
N-type VGCCs in ACC excitatory synaptic transmission
In the present study, a multi-channel recording system,
MED64, was used throughout the experiment to sort
out the layer-related differences in synaptic responses
within the ACC of adult mice. An ACC slice was placed
on top of the 8 × 8 square shaped MED64 probe as
previously reported [24,30]. We stimulated one channel
in the deep layer V and observed widespread responses
throughout the layers except layer I (Figure 1A). In the
superficial layer, especially layer II/III, most of the chan-
nels showed a great reduction after bath application of
the N-type VGCC blocker, ω-Ctx GVIA (1 μM, 15 min).
For example, the two channels within the superficial
layer (Ch. 22 and 38) both underwent similar amount
of reduction (39.2% of baseline and 38.2% of baseline,
Figure 1B). The effect of the drug was irreversible, with
the reduction not recovered until 1 h after the onset of
the drug application. The averaged fEPSP slope of 5 acti-
vated channels in the superficial layer is similar to the re-
sult of one single channel (Figure 1C). Thus, there are no
apparent differences among the channels within the same
layer. The summarized data show that the fEPSP slope
was inhibited to 45.8 ± 4.4% of baseline after applying ω-
Ctx GVIA (n = 7 slices/7 mice; Figure 1D).
To determine if the contribution of the N-type cal-
cium channel to synaptic transmission varies according
to the cortical layers, we compared the effect of ω-Ctx
GVIA in different layers in the same slice. We selectedtwo channels (Ch. 30 and 28) that had similar response
size and shape in superficial and deep layer (layer V/VI)
of the ACC, respectively (Figure 2A). Significant difference
was detected in the reduction process and the inhibited
level between the two channels after drug treatment (Ch.
30: 37.2% of baseline; Ch. 28: 51.2% of baseline; Figure 2B).
The averaged data of 5–7 channels for one single slice
(Figure 2C) and the pooled data of several mice demon-
strate the same layer-related difference (superficial layer:
45.8 ± 4.4% of baseline, deep layer: 59.6 ± 2.8% of baseline,
n = 7 slices/7 mice, t(12) = −2.663, P = 0.021; Figure 2D).
These results suggest that N-type VGCCs mediate excita-
tory synaptic transmission in the ACC and there were dif-
ferences between layers.
Role of other VGCCs in ACC synaptic transmission
We next tested the effects of other VGCC blockers in
ACC glutamatergic synaptic transmission in the superficial
layer. The P/Q-type VGCC blocker ω-Aga IVA (1 μM,
20 min) had no effect at all (Figure 3A). The level of re-
sponse was 103.0 ± 1.4% at the end of the drug treatment
and 99.5 ± 1.8% at the end of the recording (n = 5 slices/5
mice; Figure 3B). This is different from previous reports of
the predominant role of P/Q-type VGCC in excitatory syn-
aptic transmission in the hippocampus [2,4,6] and cerebel-
lum [3]. R-type VGCC has been suggested to contribute to
excitatory synaptic transmission in the rat hippocampus
[38]. We addressed the involvement of R-type calcium
channel by bath applying SNX-482 (0.5 μM, 20 min). We
found that SNX-482 did not produce any significant effect
(end of drug: 96.7 ± 1.4%, end of experiment: 97.5 ± 0.8%,
n = 6 slices/6 mice; Figure 3C and D). Next, we tested
the possible contribution of low-voltage activated T-type
VGCC by applying the T-type VGCC blocker NiCl2
(100 μM, 20 min). We found that there was no change of
the synaptic transmission in the superficial layer (end of
drug: 98.8 ± 4.4%, end of experiment: 97.8 ± 2.2%, n = 7
slices/7 mice; Figure 3E and F). Finally, we tested if the
L-type VGCC mediates the ACC synaptic transmission.
Bath infusion of nimodipine (10 μM, 20 min) failed to
produce any inhibitory effect on the slope of fEPSP re-
corded from the superficial layer of the ACC slice (end
of drug: 101.2 ± 3.3%, end of experiment: 99.2 ± 2.3%, n = 5
slices/5 mice; Figure 3G and H).
Similar results were found in the deep layer of the
ACC. The ω-Aga IVA group showed 105.2 ± 1.4% at the
end of drug treatment and 96.9 ± 1.4% at the end of experi-
ment (n = 5 slices/5 mice; Figure 4A and B). SNX-482 (end
of drug: 104.1 ± 0.7%, end of experiment: 98.0 ± 0.2%, n = 6
slices/6 mice; Figure 4C and D), NiCl2 (end of drug: 91.2 ±
3.2%, end of experiment: 97.7 ± 1.3%, n = 7 slices/7 mice;
Figure 4E and F) and nimodipine (end of drug: 99.3 ±
2.1%, end of experiment: 98.0 ± 1.9%, n = 5 slices/5 mice;
Figure 4G and H) all showed no inhibition.
Figure 2 Comparison of the effects of the N-type VGCC blocker in the superficial layer and deep layer of the ACC. A, The same slice as
Figure 1A. Two channels (Ch. 30 from LII/III and Ch. 28 from LV/VI) are selected for further comparison. B, ω-Ctx GVIA (1 μM) was bath applied for
15 min (filled circle: Ch. 30; open circle: Ch. 28) in a single slice. Sample fEPSP recordings taken at the times indicated by the corresponding numbers
are shown above the plot. Calibration: 500 μV, 20 ms. C, Averaged data of 5–7 activated channels in the superficial layer (filled circle: LII/III) and deep
layer (open circle: LV/VI) in one slice. D, Pooled data of 7 mice (LII/III: 45.8 ± 4.4% of baseline, LV/VI: 59.6 ± 2.8% of baseline, n = 7 slices/7 mice,
t(12) = −2.663, P = 0.021). ω-Ctx GVIA produced a stronger inhibition of superficial layer responses than those of the deep layer in the ACC. The
horizontal bars indicate the period of drug application. Asterisk indicates the statistical significance between superficial layer and deep layer of the
ACC slice. Error bars represent SEM.
Figure 1 Role of N-type VGCCs in ACC excitatory synaptic transmission in the superficial layer. A, A representative example of MED64
responses before (black) and after (red) ω-Ctx GVIA (1 μM) application. Stimulation (thunderbolt) was given in the deep layer (Ch. 36). The regions
are divided into Layer (L) I, II/III and V/VI (vertical lines). Two channels (Ch. 22 and Ch. 38) are selected for further comparison. B, ω-Ctx GVIA
(1 μM) was applied for 15 min (filled circle: Ch. 22; open circle: Ch. 38) in a single slice. Sample fEPSP recordings taken at the times indicated by
the corresponding numbers are shown above the plot. Calibration: 300 μV, 20 ms. C, Averaged data of 5 activated channels in the superficial layer
in one slice. D, Pooled data of 7 mice (45.8 ± 4.4% of baseline, n = 7 slices/7 mice). Application of ω-Ctx GVIA produced an irreversible inhibition
of synaptic responses recorded from the superficial layer of the ACC. The horizontal bars indicate the period of drug application. Error bars
represent SEM.
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Figure 3 Role of other VGCCs in ACC excitatory synaptic transmission in the superficial layer. A, Averaged data of 5 channels in the superficial
layer in one slice, showing the effect of applying ω-Aga IVA (1 μM) for 20 min. B, Pooled data of 5 mice (99.5 ± 1.8% of baseline, n = 5 slices/5 mice).
C, Averaged data of 6 channels in the superficial layer in one slice, showing the effect of applying SNX-482 (0.5 μM) for 20 min. D, Pooled data of 6
mice (97.5 ± 0.8% of baseline, n = 6 slices/6 mice). E, Averaged data of 5 channels in the superficial layer in one slice, showing the effect of applying
NiCl2 (100 μM) for 20 min. F, Pooled data of 7 mice (97.8 ± 2.2% of baseline, n = 7 slices/7 mice). G, Averaged data of 5 channels in the superficial layer
in one slice, showing the effect of applying nimodipine (10 μM) for 20 min. H, Pooled data of 5 mice (99.2 ± 2.3% of baseline, n = 5 slices/5 mice). All
drugs infused had no effect on synaptic transmission in the superficial layer of the ACC. The horizontal bars indicate the period of drug application.
Error bars represent SEM.
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treatment groups in the superficial layer was statistically
significant (F(4,25) = 16.00, P = 0.003, One-way ANOVA
in ranks with Dunn’s post-hoc; P < 0.05 between N-type
and all other groups, Figure 5A). There was also signifi-
cant difference in the deep layer (F(4,25) = 93.53, P < 0.001,
One-way ANOVA with Bonferroni’s post-hoc; P < 0.001
between N-type and all other groups, Figure 5B). Overall,
N-type is the predominant VGCC involved in excitatory
synaptic transmission in the ACC. Other VGCCs we
tested do not participate in the ACC glutamatergic synap-
tic transmission.
Modulation of ACC synaptic transmission
We next investigated whether the ACC synaptic trans-
mission is responsive to the modulation exerted by sev-
eral neuromodulators in the brain. Neuromodulators
are signals that trigger activation or inhibition of theneurons and many of them are known to affect VGCCs
[4,39-41]. Because only the N-type VGCC blocker showed
a significant reduction in the ACC synaptic transmis-
sion, we decided to apply several neuromodulators with
or without the presence of ω-Ctx GVIA (1 μM). 1S,3R–
ACPD (200 μM, 10 min), an mGluR agonist, was first
tested without applying ω-Ctx GVIA (Figure 6A). One
channel in the superficial layer (Ch. 19) and the other in
the deep layer (Ch. 38) were selected to compare its ef-
fect. The drug induced a great inhibition during the treat-
ment and after washout the response recovered to the
baseline level in both superficial and deep layers. The re-
duction extent of deep layer during drug application was
less than that of the superficial layer (Ch. 19: 22.0% of
baseline; Ch. 38: 44.6% of baseline, Figure 6B). This trend
was also seen in the averaged data of 5–7 channels in one
slice (Figure 6C). Pooled data from 7 animals show the
same layer-related difference (LII/III: 23.2 ± 6.5%, LV/VI:
Figure 4 Role of other VGCCs in ACC excitatory synaptic transmission in the deep layer. A, Averaged data of 6 channels in the deep layer in one
slice, showing the effect of applying ω-Aga IVA (1 μM) for 20 min. B, Pooled data of 5 mice (96.9 ± 1.4% of baseline, n = 5 slices/5 mice). C, Averaged data
of 8 channels in the deep layer in one slice, showing the effect of applying SNX-482 (0.5 μM) for 20 min. D, Pooled data of 6 mice (98.0 ± 0.2% of baseline,
n = 6 slices/6 mice). E, Averaged data of 6 channels in the deep layer in one slice, showing the effect of applying NiCl2 (100 μM) for 20 min. F, Pooled
data of 7 mice (97.7 ± 1.3% of baseline, n = 7 slices/7 mice). G, Averaged data of 7 channels in the deep layer in one slice, showing the effect of applying
nimodipine (10 μM) for 20 min. H, Pooled data of 5 mice (98.0 ± 1.9% of baseline, n = 5 slices/5 mice). All drugs infused had no effect on synaptic
transmission in the deep layer of the ACC. The horizontal bars indicate the period of drug application. Error bars represent SEM.
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Figure 6D).
To compare the inhibitory effects among different
neuromodulators, we sequentially applied several drugs
to the same slice. After the application of 1S,3R–ACPD
(200 μM) for 10 min, we then applied GABAB receptor
agonist (R)-Baclofen (5 μM) for 5 min, adenosine recep-
tor agonist 2-CA (5 μM) for 5 min and finally choliner-
gic receptor agonist carbachol (Cch, 10 μM) for 10 min
(Figure 6E). In a previous study of the hippocampus,
these drugs all inhibited the synaptic transmission im-
mediately after they were applied with full recovery after
washout [4]. We found similar results in the ACC slices
but the recovery was partial after the washout. In the
superficial layer, 1S,3R–ACPD inhibited the response to
25.7 ± 3.9% of baseline, (R)-Baclofen to 19.7 ± 2.8%, 2-CA
to 49.4 ± 5.5%, and Cch to 38.5 ± 4.2% (n = 5 slices/5 mice).
The magnitude of inhibition induced by the drugs in the
deep layer was: 1S,3R–ACPD 47.5 ± 2.3%, (R)-Baclofen48.8 ± 2.2%, 2-CA 52.9 ± 5.2% and Cch 42.6 ± 2.5% (n = 5
slices/5 mice). Generally, there was statistically significant
difference between layers (F(1,8) = 6.427, P = 0.035, Re-
peated two-way ANOVA). Post hoc Bonferroni analysis
revealed statistical differences between LII/III and LV/VI
for 1S,3R–ACPD (P = 0.013) and (R)-Baclofen (P < 0.001).
2-CA (P = 0.673) and Cch (P = 0.714) showed no layer-
related difference (see Figure 6E). Analysis of the reduc-
tion index obtained the same results (Figure 6F). Both
1S,3R–ACPD and (R)-Baclofen produced a much stronger
inhibition in the superficial layer than in the deep layer
(P < 0.001 for both drugs).
We next checked whether these effects will change
after applying ω-Ctx GVIA (1 μM, 15 min) to block N-
type VGCC-mediated synaptic transmission (Figure 7A-C).
Similarly, ω-Ctx GVIA induced irreversible synaptic inhib-
ition even after washout. We then applied the neuromodu-
lator as Figure 6E. All the drugs still produced inhibition of
the fEPSP recorded from the ACC. The inhibited values in
Figure 5 The predominant role of N-type VGCC in ACC excitatory
synaptic transmission. A, The difference in the reduction index
(100% - the normalized fEPSP slope value of the last 4 min of the
experiment) among the drug treatment groups in the superficial layer
is statistically significant (F(4,25) = 16.00, P = 0.003, One-way ANOVA in
ranks with Dunn’s post-hoc; P < 0.05 between N-type and all other
groups). B, The difference in the deep layer is also statistically
significant (F(4,25) = 93.53, P < 0.001, One-way ANOVA with Bonferroni’s
post-hoc; P < 0.001 between N-type and all other groups). Error bars
represent SEM.
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Baclofen 14.8 ± 0.3%, 2-CA 19.2 ± 1.9%, Cch 14.0 ± 0.7%
(n = 5 slices/5 mice, Figure 7C). In the deep layer, the
values were: 1S,3R–ACPD 12.3 ± 3.7%, (R)-Baclofen 14.4 ±
4.8%, 2-CA 22.8 ± 1.1%, Cch 18.5 ± 2.1% (n = 5 slices/5
mice, Figure 7C). Repeated two-way ANOVA detected the
statistically significant differences between layers (F(1,8) =
7.069, P = 0029). However, post doc Bonferroni test failed
to show any layer-related significant change for all of the
four drugs (Figure 7D). Thus, although the N-type VGCC
blocker did not prevent neuromodulators-induced synaptic
inhibition, it abolished the layer difference in the effects of
1S,3R–ACPD and (R)-Baclofen.To further elucidate the mechanisms for this loss of
layer difference, we normalized the 70–90 min period of
Figure 7C as 100% and checked the reduction index of the
neuromodulators again (Figure 7E). We found that 1S,3R–
ACPD inhibited the ω-Ctx GVIA-insensitive responses
from the deep layer to a greater extent than those in the
superficial layer (LII/III: 54.6 ± 7.0%, LV/VI: 77.7 ± 5.0%,
P = 0.007). The layer difference was not clear for Baclofen
(LII/III: 59.3 ± 2.9%, LV/VI: 75.0 ± 6.3%, P = 0.057), 2-CA
(LII/III: 46.3 ± 8.3%, LV/VI: 55.4 ± 6.5%, P = 0.262) and
Cch (LII/III: 61.9 ± 1.5%, LV/VI: 64.8 ± 4.3%, P = 0.719,
Figure 7E). Comparison of the reduction index with and
without the presence of ω-Ctx GVIA reached the same
conclusion for the layer difference (Figure 7F and G).
These data suggest that 1S,3R–ACPD possibly acts more
in the deep layer with different mechanisms when the
N-type VGCC was blocked.Whole-cell patch-clamp recordings of synaptic transmission
in the ACC
To confirm the MED64 data, we performed whole-
cell patch-clamp recordings in the ACC LII/III neu-
rons (Figure 8). Three VGCC blockers were bath
infused for 30 min and only ω-Ctx GVIA showed the
blocking effect in the ACC synaptic transmission (ω-
Ctx GVIA: 39.2 ± 7.0% of baseline, n = 10 cells/6 mice;
nimodipine: 101.2 ± 3.0% of baseline, n = 10 cells/6
mice; NiCl2: 99.6 ± 5.1% of baseline, n = 10 cells/6
mice; Figure 8A-C). In addition, we also applied the
neuromodulators and examined their influence on the
EPSCs recorded from the superficial layer of the
ACC. Similarly, we found that all of the four drugs
produced an acute inhibition that can be fully or par-
tially recovered after washout (1S,3R–ACPD: 200 μM,
29.1 ± 5.1% of baseline; Cch: 10 μM, 46.7 ± 6.2% of
baseline; (R)-Baclofen: 5 μM, 41.7 ± 2.0% of baseline;
2-CA: 5 μM, 29.9 ± 5.3% of baseline; n = 8 cells/4
mice; Figure 8D-G). Nevertheless, comparison of the
whole-cell and MED64 data revealed some differences
in the reduction extent and recover process of the
drug effect. For example, 2-CA produced a much lar-
ger extent of reduction in EPSCs (29.9 ± 5.3% of base-
line at the end of the drug treatment, n = 8 cells/4
mice, Figure 8G) as compared to its effect on fEPSPs
(49.4 ± 5.5% of baseline at the end of the drug treat-
ment, n = 5 slices/5 mice, Figure 6E). Also, while the 2-
CA-induced fEPSP inhibition is fully reversible (Figure 6E),
the suppression of EPSCs cannot be recovered (Figure 8G).
This discrepancy may be attributed to differences in
experimental variables such as the recording method
(whole-cell patch-clamp recording vs. multi-channel
field potential recording) and drug infusion time
(30 min vs. 5 min).
Figure 6 Effect of neuromodulators on ACC excitatory synaptic transmission. A, A representative example of MED64 responses before (black)
and after (red) 1S,3R–ACPD (200 μM) application. Stimulation (thunderbolt) was given in the deep layer (Ch. 37). Two channels (Ch. 19 from LII/III and
Ch. 38 from LV/VI) are selected for further comparison. B, 1S,3R–ACPD (200 μM) was bath applied for 10 min (filled circle: Ch. 19; open circle: Ch. 38) in
a single slice. Sample fEPSP recordings taken at the times indicated by the corresponding numbers are shown above the plot. Calibration: 300 μV,
20 ms. C, Averaged data of 5–7 activated channels in the superficial layer and deep layer in one slice. D, Pooled data of 7 mice (LII/III: 23.2 ± 6.5% of
baseline, LV/VI: 42.7 ± 5.5% of baseline, n = 7 slices/7 mice). Bath application of 1S,3R-ACPD resulted in an acute inhibition that gradually recovered after
washout. The superficial layer response exhibited a much more reduction than the deep layer. E, Four neuromodulators were sequentially applied.
Significant differences could be found in the blocking effect of 1S,3R–ACPD and (R)-Baclofen between individual layers (n = 5 slices/5 mice). The
horizontal bars indicate the period of drug application. Error bars represent SEM. F, Reduction index of the neuromodulators. 1S,3R–ACPD (LII/III:
74.3% ± 8.8%, LV/VI: 52.5 ± 2.3%, P = 0.003) and (R)-Baclofen (LII/III: 80.3 ± 2.8%, LV/VI: 51.1 ± 2.2%, P = 0.002) showed statistically significant difference
between the layers. 2-CA (LII/III: 50.6 ± 5.5%, LV/VI: 47.1 ± 5.2%, P = 0.614) and Cch (LII/III: 61.5 ± 4.2%, LV/VI: 57.3 ± 2.5%, P = 0.538) exhibited no
layer-related difference.
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In this study, we have demonstrated the prominent role
of N-type VGCC in mediating glutamatergic synaptic
transmission in the adult mice ACC. We have used
the newly-developed MED64 system to record multi-
site synaptic responses in the coronal ACC slices and
compare the possible layer-related differences. Several
types of VGCC blockers were tested in the basal syn-
aptic transmission and only ω-Ctx GVIA, the N-type
VGCC blocker, showed a great reduction. Moreover, the
superficial layer had a greater inhibition than the deep
layer. We also tested whether ω-Ctx GVIA would influ-
ence the modulatory effect of several neuromodulators
on excitatory synaptic transmission in the ACC. We
found that the neuromodulator effects were not greatly
affected by ω-Ctx GVIA.N- and P/Q-type VGCC in the ACC
N- and P/Q-type calcium channels are the major VGCCs
for Ca2+ influx to initiate the fast release of neurotrans-
mitters/neuromodulators such as glutamate, acetylcholine,
and GABA [42]. Both channels are high-voltage activated
channels consisting of the α1 subunit pore. N-type VGCC
comprises an α1B subunit or Cav2.2 and the channel is pri-
marily in the presynaptic compartment [8,18,42]. ω-Ctx
GVIA was commonly used to antagonize the activity of
N-type VGCC [1,4,6,18,20]. There are studies demon-
strating the up-regulation of N-type VGCC subunit in
the primary afferent neurons after tissue inflammation
and nerve injury [12,43,44]. There is an N-type VGCC-
targeting drug (Ziconotide) used in the clinic to relieve
neuropathic and inflammation pain. However, its clinical
application is limited by the accompanying central side
Figure 7 Effect of neuromodulators after blocking N-type VGCC. A, Results of one channel applying each drug sequentially (filled circle: LII/III, open
circle: LV/VI): ω-Ctx-GVIA (1 μM) for 15 min, 1S,3R–ACPD (200 μM) for 10 min, (R)-Baclofen (5 μM) for 5 min, 2-CA (5 μM) for 5 min and Cch (10 μM) for
10 min. B, Averaged data (n = 6–8 channels/1 slice) of each layer that showed response in one slice. C, Pooled data of 5 mice. Pre-exposure of the ACC
slice with ω-Ctx-GVIA abolished the layer-related difference in the effect of 1S,3R–ACPD and (R)-Baclofen (n = 5 slices/5 mice). The horizontal bars indicate
the period of drug application. Error bars represent SEM. D, Reduction index of ω-Ctx-GVIA and neuromodulators in different layers. All drugs showed no
statistically significant difference between layers. E, Reduction index of neuromodulators when ω-Ctx-GVIA-insensitive responses (70–90 min in Figure 7C)
were normalized as 100%. 1S,3R–ACPD inhibited the ω-Ctx GVIA-insensitive responses more in the deep layer (LII/III: 54.6 ± 7.0%, LV/VI: 77.7 ± 5.0%,
P= 0.007). The layer difference was not clear for Baclofen (LII/III: 59.3 ± 2.9%, LV/VI: 75.0 ± 6.3%, P = 0.057), 2-CA (LII/III: 46.3 ± 8.3%, LV/VI: 55.4 ± 6.5%,
P= 0.262) and Cch (LII/III: 61.9 ± 1.5%, LV/VI: 64.8 ± 4.3%, P = 0.719). F, Reduction index of each agonist in the superficial layer with (Figure 6F) or
without ω-Ctx GVIA (Figure 7E). G, Reduction index of each agonist in the deep layer with (Figure 6F) or without ω-Ctx GVIA (Figure 7E).
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ies provide strong evidence that N-type calcium channels
play important roles in the ACC synaptic transmission,
and the inhibitory effect of the N-type VGCC blocker in
the ACC may explain some of the side effects caused by
Ziconotide.
P/Q-type VGCC consists of an α1A subunit or Cav2.1
and ω-Aga IVA is the well-known antagonist. Several stud-
ies show that dysfunction of this channel induces ataxia,
migraine, vertigo and epilepsy [45-48]. The involvement ofP/Q-type VGCC in central synaptic transmission and plas-
ticity has been extensively studied in the hippocampus
[2,4,6], cerebellum [3] and nucleus accumbens [49]. How-
ever, there are no studies of N- and P/Q-type VGCC en-
gagement in the adult mice ACC. Our results revealed a
dramatic reduction of glutamatergic synaptic transmission
by the N-type VGCC blocker in the ACC. Since the excita-
tory synaptic responses in the ACC are mediated predom-
inantly by AMPA/kainate receptors, the explanation for
ω-Ctx GVIA-induced inhibition would be the reduction
Figure 8 Whole-cell patch-clamp recordings of the synaptic responses in the ACC: N-type VGCC involvement and modulation by
neuromodulators. A, ω-Ctx-GVIA (1 μM, 30 min) treatment blocked the EPSCs recorded from LII/III neurons of the ACC (39.2 ± 7.0%, n = 10
cells/6 mice). Sample traces are shown in the insets. B, C, Nimodipine (10 μM, 30 min, 101.2 ± 3.0%, n = 10 cells/6 mice) and NiCl2 (100 μM,
30 min, 99.6 ± 5.1%, n = 10 cells/6 mice) did not block the synaptic response. Sample traces of nimodipine treatment are shown in the insets.
D-F, Application of 1S,3R–ACPD (200 μM, 29.1 ± 5.1%, n = 8 cells/4 mice), Cch (10 μM, 46.7 ± 6.2%, n = 8 cells/4 mice) and (R)-Baclofen (5 μM,
41.7 ± 2.0%, n = 8 cells/4 mice) for 30 min inhibited the ACC LII/III neuronal responses and the inhibition was recovered after washout. G, 2-CA (5 μM,
29.9 ± 5.3%, n = 8 cells/4 mice) induced a similar acute inhibition but the inhibition is maintained during washout. The horizontal bars indicate the
period of drug application. Error bars represent SEM.
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Ctx GVIA produced a much stronger inhibition of the
superficial layer responses than those of the deep layer,
indicating that the expression density of the N-type
VGCC in the ACC may have layer-related difference. Fu-
ture studies are required to address this issue by using
morphological tools to investigate the distribution of
VGCCs across each layer of the ACC.
The current findings show other VGCC blockers did not
significantly inhibit ACC synaptic response. These resultsdiffer from previous reports in other brain regions, which
involve the combination of N- and P/Q-type VGCCs in
excitatory synaptic transmission [9,10]. The possibility
of low doses of the drugs causing the negative results is
unlikely, because the drug concentrations used in the
present experiment are not lower compared to other
studies [4,10,49]. According to the in situ hybridization
data from Allen Institute for Brain Sciences, all types of
VGCCs are expressed in the ACC. Therefore, they may
exert some other functions rather than mediating the
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shown in our previous studies that L-type VGCC is in-
volved in low frequency stimulation-induced long-term
depression in the ACC [30,50]. Taken together, these find-
ings indicate that different central synapses in the brain
may depend on different types of VGCCs for mediation of
the excitatory synaptic transmission. Notably, however,
ω-Ctx GVIA only blocked about 50% of the total synaptic
transmission in the ACC. Therefore, it is still necessary for
future studies to identify the receptors or channels mediat-
ing the remaining 50% of the ACC synaptic response in
the basal condition.
VGCCs and neuromodulators in the ACC
N-, P/Q-, R-, and L- type VGCCs are all involved in pre-
synaptic neurotransmitter release [9,42] and it has been
reported that different neuromodulators affect these
VGCCs [4,39-41]. Thus, we wanted to test the effect of
ω-Ctx GVIA on the modulation of ACC synaptic trans-
mission exerted by various neuromodulators. We have
applied four neuromodulators with or without the pres-
ence of ω-Ctx GVIA. All drugs induced a great acute in-
hibition of the fEPSP under both conditions and the
inhibitive effect is reversible after washout. These results
are partially consistent with the previous reports in the
hippocampus [4]. Interestingly, the layer-related differ-
ence regarding the inhibitory effect of 1S,3R–ACPD and
(R)-Baclofen is abolished after blocking N-type VGCC-
mediated synaptic transmission. One possible explan-
ation for layer-related difference is different distribution
of mGluRs (for 1S,3R–ACPD) and GABAB (for (R)-Bac-
lofen) among synapses in the superficial vs deep layers of
the ACC. Future studies are needed to further investigate
these mechanisms via a combination of electrophysio-
logical and morphological approaches.
The modulation of synaptic transmission by 1S,3R–
ACPD in the ACC is consistent with the previous reports
in other brain areas, such as hippocampus [4,51-53], neo-
cortex [54], cerebellum [55] and striatum [56]. These data
are also consistent with the previous results showing the in-
hibition of N-type and other types of VGCC currents by
the 1S,3R-ACPD [57-63]. It is likely that 1S,3R-ACPD pro-
duces its inhibitory effect by intracellular G protein coupled
signaling pathways. Considering the fact that 1S,3R-ACPD
is a non-selective mGluR antagonist [64,65], future studies
are needed to examine the subtypes of mGluRs and their
related downstream signaling pathways mediating the in-
hibitory effects.
In summary, our present study is the first to establish
the importance of N-type VGCC in mediating excitatory
synaptic transmission in the adult mice ACC. ACC is
known to be an important region for memory and chronic
pain [22,23]. Due to its important roles in normal synaptic
transmission in the ACC, our results provide possibleexplanations for the central side effects produced by the
N-type calcium channel blockers applied intrathecally or
systemically in the clinic.
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